Efruxifermin is a fusion protein commercialized by Akero Therapeutics, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 1 is ongoing, 3 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Efruxifermin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Efruxifermin is expected to reach an annual total of $280 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Efruxifermin Overview

Efruxifermin (AKR-001) is under development for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes and cirrhosis due to NASH. The drug candidate is a long-acting fibroblast growth factor 21 (FGF21) analog. It is a fusion protein obtained by the fusion of Fc domain of human IgG1 to the N-terminus of human mature FGF21 via a linker peptide. The drug candidate acts by targeting fibroblast growth factor receptors 1, 2, 3. It is administered through subcutaneous route. It was also under development for obesity.

Akero Therapeutics Overview

Akero Therapeutics is a clinical-stage cardio-metabolic company. The company develops transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. It also develop medicines for the treatment of metabolic diseases. The company is funded by Atlas Venture, ATP, venBio Partners and Versant Ventures. The company has offices in Massachusetts and California. Akero Therapeutics is headquartered in California, US.

The operating loss of the company was US$115.2 million in FY2022, compared to an operating loss of US$100.9 million in FY2021. The net loss of the company was US$112 million in FY2022, compared to a net loss of US$100.8 million in FY2021.

For a complete picture of Efruxifermin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.